sorafenib has been researched along with crizotinib in 19 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (crizotinib) | Trials (crizotinib) | Recent Studies (post-2010) (crizotinib) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,780 | 112 | 1,718 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 6 (31.58) | 2.80 |
| Authors | Studies |
|---|---|
| Archibald, H; Dowell, L; Drew, L; Erlander, MG; Gray, NS; Greninger, P; Haber, DA; Hanke, JH; Iafrate, AJ; Lamb, J; Lee, D; Ma, XJ; Maheswaran, S; McDermott, U; Montagut, C; Njauw, CN; Raudales, R; Rothenberg, SM; Settleman, J; Sharma, SV; Sordella, R; Supko, JG; Tam, A; Tsao, H; Ulkus, LE | 1 |
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bullock, AN; Canning, P; Choi, S; Cuny, GD; Mohedas, AH; Sanvitale, CE; Wang, Y; Xing, X; Yu, PB | 1 |
| Guo, M; He, J; Jiang, X; Jiang, Y; Li, J; Liu, J; Ouyang, L; Wang, J; Zhang, J; Zhang, S | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Chen, F; Zhuang, C | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Friedrich, MJ | 1 |
| Brentani, RR; Cooke, VG; Damascena, A; Duncan, MB; Kalluri, R; Keskin, D; Khan, Z; LeBleu, VS; Maeda, G; O'Connell, JT; Rocha, RM; Sugimoto, H; Teng, Y; Vong, S; Xie, L | 1 |
| He, K; Yu, J; Zhang, L; Zheng, X | 1 |
| de Bont, ES; den Dunnen, WF; Hoving, EW; Kampen, KR; Lourens, HJ; Meeuwsen-de Boer, TG; Scherpen, FJ; Sie, M; Zomerman, WW | 1 |
| Nishio, K; Togashi, Y | 1 |
| Bonsignore, R; Gentile, C; Lauria, A; Martorana, A | 1 |
| Beizaei, K; Bußmann, L; Gleißner, L; Hoffer, K; Kriegs, M; Laban, S; Möckelmann, N; Münscher, A; Petersen, C; Rothkamm, K; Steinmeister, L; Vu, AT | 1 |
| Amaria, RN; Call, SG; Falchook, GS; Holley, VR; Hong, DS; Huang, HJ; Janku, F; Kato, S; Meric-Bernstam, F; Naing, A; Patel, SP; Piha-Paul, SA; Sakamuri, D; Tsimberidou, AM; Zinner, RG | 1 |
| Brezinová, B; Chovanec, M; Dubovan, P; Gomolčáková, J; Jurišová, S; Mardiak, J; Mego, M; Rejlekova, K | 1 |
| Li, H; Liu, X; Zhang, J; Zhong, T | 1 |
| Ci, H; Dong, Q; Du, W; Fu, Y; Jia, H; Shen, K; Wang, X; Zhou, J | 1 |
4 review(s) available for sorafenib and crizotinib
| Article | Year |
|---|---|
Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Topics: Antineoplastic Agents; Drug Discovery; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridines; Quinazolines; Quinolones; Receptors, Vascular Endothelial Growth Factor; Small Molecule Libraries | 2016 |
Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives.
Topics: Animals; Cell Line, Tumor; Drug Development; Humans; Molecular Structure; Necroptosis; Protein Kinase Inhibitors; Receptor-Interacting Protein Serine-Threonine Kinases | 2020 |
[Kinase inhibitors and their resistance].
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Biomarkers, Tumor; Crizotinib; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sorafenib; Sulfonamides; Trastuzumab; Vemurafenib | 2015 |
Kinase Inhibitors in Multitargeted Cancer Therapy.
Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2017 |
15 other study(ies) available for sorafenib and crizotinib
| Article | Year |
|---|---|
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genotype; Humans; Neoplasms; Protein Kinase Inhibitors | 2007 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Topics: Activin Receptors, Type I; Aminopyridines; Humans; Mutation; Myositis Ossificans; Phenols; Protein Kinase Inhibitors; Structure-Activity Relationship | 2014 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
NSCLC drug targets acquire new visibility.
Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome | 2011 |
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Crizotinib; Epithelial-Mesenchymal Transition; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Metastasis; Niacinamide; Pericytes; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Tumor Cells, Cultured | 2012 |
Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Colonic Neoplasms; Crizotinib; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Quinazolines; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma.
Topics: Apoptosis; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Crizotinib; Dasatinib; Ependymoma; Extracellular Signal-Regulated MAP Kinases; Humans; Intercellular Signaling Peptides and Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridines; Signal Transduction; Sorafenib | 2015 |
Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crizotinib; ErbB Receptors; Head and Neck Neoplasms; Humans; Indoles; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Sorafenib; Sulfonamides | 2019 |
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell-Free Nucleic Acids; Crizotinib; Female; Humans; Male; Middle Aged; Mutation; Neoplasms; Proto-Oncogene Proteins B-raf; Sorafenib; Vemurafenib | 2021 |
Targeted therapy in Xp11 translocation renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Chromosomes, Human, X; Crizotinib; Disease Progression; Everolimus; Fatal Outcome; Female; Humans; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Nivolumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Sorafenib; Sulfonamides; Sunitinib; Tomography, X-Ray Computed | 2021 |
Co-delivery of sorafenib and crizotinib encapsulated with polymeric nanoparticles for the treatment of
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Chemistry, Pharmaceutical; Crizotinib; Drug Carriers; Drug Combinations; Drug Liberation; Human Umbilical Vein Endothelial Cells; Humans; Lung Neoplasms; Mice, Nude; Nanoparticles; Polymers; Sorafenib; Xenograft Model Antitumor Assays | 2021 |
An Angiogenic Gene Signature for Prediction of the Prognosis and Therapeutic Responses of Hepatocellular Carcinoma.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Hepatocellular; Crizotinib; Humans; Liver Neoplasms; Sorafenib | 2023 |